JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB257789

Human USP22 knockout HeLa cell lysate

Be the first to review this product! Submit a review

|

(0 Publication)

USP22 KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp deletion in exon 1.

View Alternative Names

Deubiquitinating enzyme 22, KIAA1063, UBP22_HUMAN, USP3L, Ubiquitin carboxyl-terminal hydrolase 22, Ubiquitin specific peptidase 22, Ubiquitin specific peptidase 3 like, Ubiquitin specific protease 22, Ubiquitin thioesterase 22, Ubiquitin thiolesterase 22, Ubiquitin-specific-processing protease 22

3 Images
Western blot - Human USP22 knockout HeLa cell lysate (AB257789)
  • WB

Lab

Western blot - Human USP22 knockout HeLa cell lysate (AB257789)

Lane 1 : Wild-type HeLa cell lysate 20 μg
Lane 2 : USP22 knockout HeLa cell lysate 20 μg
False colour image of Western blot : Anti-USP22 antibody [EPR18945] staining at 1/2000 dilution, shown in green; Mouse anti-GAPDH antibody [6C5] (ab8245) loading control staining at 1/20000 dilution, shown in red. In Western blot, ab195289 was shown to bind specifically to USP22. A band was observed at 59 kDa in wild-type HeLa cell lysates with no signal observed at this size in usp22 knockout cell line ab264888 (knockout cell lysate ab257789). To generate this image, wild-type and usp22 knockout HeLa cell lysates were analysed. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in fluorescent western blot (TBS-based) blocking solution before incubation with primary antibodies overnight at 4°C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged.Secondary antibodies used were Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (ab216776) at 1/20000 dilution.

All lanes:

Western blot - Anti-USP22 antibody [EPR18945] (<a href='/en-us/products/primary-antibodies/usp22-antibody-epr18945-ab195289'>ab195289</a>) at 1/2000 dilution

Lane 1:

Western blot - Human USP22 knockout HeLa cell lysate (ab257789)

Lane 1:

Wild-type HeLa cell lysate at 20 µg

Lane 2:

USP22 knockout HeLa cell lysate at 20 µg

Lane 2:

Western blot - Human USP22 knockout HeLa cell line (<a href='/en-us/products/cell-lines/human-usp22-knockout-hela-cell-line-ab264888'>ab264888</a>)

Predicted band size: 60 kDa

Observed band size: 59 kDa

false

Sanger Sequencing - Human USP22 knockout HeLa cell lysate (AB257789)
  • Sanger seq

Unknown

Sanger Sequencing - Human USP22 knockout HeLa cell lysate (AB257789)

Homozygous : 1 bp deletion in exon 1

Western blot - Human USP22 knockout HeLa cell lysate (AB257789)
  • WB

Lab

Western blot - Human USP22 knockout HeLa cell lysate (AB257789)

Lane 1 : Wild-type HeLa cell lysate 20 μg
Lane 2 : USP22 knockout HeLa cell lysate 20 μg
False colour image of Western blot : Anti-USP22 antibody [EPR4352(2)] staining at 1/1000 dilution, shown in green; Mouse anti-GAPDH antibody [6C5] (ab8245) loading control staining at 1/20000 dilution, shown in red. In Western blot, ab109435 was shown to bind specifically to USP22. A band was observed at 59 kDa in wild-type HeLa cell lysates with no signal observed at this size in usp22 knockout cell line ab264888 (knockout cell lysate ab257789). To generate this image, wild-type and usp22 knockout HeLa cell lysates were analysed. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in fluorescent western blot (TBS-based) blocking solution before incubation with primary antibodies overnight at 4°C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (ab216776) at 1/20000 dilution.

All lanes:

Western blot - Anti-USP22 antibody [EPR4352(2)] (<a href='/en-us/products/primary-antibodies/usp22-antibody-epr43522-ab109435'>ab109435</a>) at 1/1000 dilution

Lane 1:

Wild-type HeLa cell lysate at 20 µg

Lane 2:

Western blot - Human USP22 knockout HeLa cell lysate (ab257789) at 20 µg

Predicted band size: 60 kDa

Observed band size: 59 kDa

false

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Knockout validation

Sanger Sequencing,Western blot

Mutation description

Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp deletion in exon 1.

Disease

Adenocarcinoma

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "Sanger seq": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" }, "WB": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }

Product details

Knockout cell lysate achieved by CRISPR/Cas9.

REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.

User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "1Kit": { "sellingSize": "1 Kit", "publicAssetCode":"ab257789-1Kit", "assetComponentDetails": [ { "size":"1 x 100 µg", "name":"Human USP22 knockout HeLa cell lysate", "number":"AB257789-CMP02", "productcode":"" }, { "size":"1 x 100 µg", "name":"Human wild-type HeLa cell lysate", "number":"AB257789-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
USP22
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing, Western blot
Zygosity
Homozygous
Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

USP22 also known as ubiquitin-specific protease 22 is an enzyme belonging to the class of deubiquitinating enzymes (DUBs). It is characterized by the ability to remove ubiquitin moieties from target proteins which can alter their stability and function. Carrying an approximate mass of 59 kDa USP22 localizes mainly in the nucleus. Expression of USP22 is widespread across a range of tissues with higher levels identified in tissues exhibiting high proliferative capacity.
Biological function summary

Removal of ubiquitin by USP22 regulates gene expression by modulating histone modifications. USP22 acts as a part of the Spt-Ada-Gcn5 acetyltransferase (SAGA) complex which plays a significant role in transcriptional regulation. Through its deubiquitinating activity USP22 alters the ubiquitination status of histone proteins thereby impacting chromatin dynamics and gene transcription.

Pathways

USP22 takes part in critical pathways like the ubiquitin-proteasome system and chromosome structure modulation. Within these processes USP22 closely interacts with proteins such as SAGA complex members and histone H2B. Its activity within this system highlights roles in transcriptional control and cellular growth important for maintaining cellular homeostasis and regulating cell cycle progression.

USP22 shows strong implications in several types of cancer including colorectal and prostate cancer. Abnormal expression levels can alter the transcriptional landscape contributing to tumor progression and metastasis. Further USP22 links to other proteins like MYC in the cancer context highlighting its importance in oncogenic pathways. This connection suggests that targeting USP22 might offer therapeutic potential in treating cancers where its expression is dysregulated.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com